Lung cancer is the leading cause of cancer-related death worldwide. Despite several
chemotherapeutic agents, a survival plateau has been reached, so new treatment strategies …

Rash and other cutaneous adverse events are class-effect toxicities seen with therapeutic
agents such as the small-molecule tyrosine kinase inhibitors erlotinib and gefitinib and …

There is considerable evidence that epidermal growth factor receptor (EGFR) plays an
important role in non–small-cell lung cancer tumor growth and proliferation. Clinical …

Advances in the knowledge of tumor biology and mechanisms of oncogenesis has granted
the singling out of several molecular targets for non-small cell lung cancer (NSCLC) …

Targeted therapies focus on signaling pathways in cancer cells and other molecular
processes involved in oncogenesis. Recent approaches affect the following major groups …

The human epidermal growth factor receptor (EGFR) signaling is overexpressed in many
solid malignancies, making it an appealing target for biologic agents. A number of agents …

Following the approval of bevacizumab, an antibody targeting VEGF-A, for advanced non-
squamous non–small cell lung cancer (NSCLC) in 2006, intensive efforts were put into the …

Skin toxicities are the most common side effects associated with the epidermal growth factor
receptor inhibitor erlotinib, occurring in most patients receiving the drug. Clinical trials …

Tyrosine kinase inhibitors (TKIs) that target epidermal growth factor receptor (EGFR) have
dramatically improved progression-free survival in non-small-cell lung cancer (NSCLC) …

BACKGROUND: Dermatological toxicity, usually in the form of acneiform rash, is frequently
observed in non-small-cell lung cancer (NSCLC) patients treated with anti-EGF receptor …